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Vitronectin and plasminogen activator inhibitor-1 (PAI-1)
are important physiological binding partners that work in concert to regulate cellular adhesion, migration, and fibrinolysis.
The high affinity binding site for PAI-1 is located within the
N-terminal somatomedin B domain of vitronectin; however,
several studies have suggested a second PAI-1-binding site
within vitronectin. To investigate this secondary site, a vitronectin mutant lacking the somatomedin B domain (r⌬sBVN) was
engineered. The short deletion had no effect on heparin-binding, integrin-binding, or cellular adhesion. Binding to the urokinase receptor was completely abolished while PAI-1 binding
was still observed, albeit with a lower affinity. Analytical ultracentrifugation on the PAI-1-vitronectin complex demonstrated
that increasing NaCl concentration favors 1:1 versus 2:1 PAI-1vitronectin complexes and hampers formation of higher order
complexes, pointing to the contribution of charge-charge interactions for PAI-1 binding to the second site. Furthermore, fluorescence resonance energy transfer between differentially labeled
PAI-1 molecules confirmed that two independent molecules of
PAI-1 are capable of binding to vitronectin. These results support a
model for the assembly of higher order PAI-1-vitronectin complexes via two distinct binding sites in both proteins.

First identified as serum-spreading factor, vitronectin was
recognized as a protein in serum capable of promoting cellular
adhesion and spreading (1). After these initial findings, further
roles for vitronectin in maintaining hemostasis, wound healing,
angiogenesis, and tumor metastasis have been elucidated based
on the diverse number of ligands with which it interacts.
Vitronectin works to regulate hemostasis via interactions with
heparin and PAI-1.2 Vitronectin competes for heparin binding
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with both thrombin and antithrombin, effectively reducing the
anticoagulant ability of heparin (2). Because PAI-1 inhibits
plasminogen activators that convert plasminogen into the protease plasmin, vitronectin acts to prevent fibrinolysis by prolonging the functional lifespan of PAI-1 and localizing it to
fibrin clots (3).
A high resolution structure of vitronectin has not been determined, although a model of the domains of vitronectin was
proposed based on computer-calculated structure predictions
using threading and docking algorithms (4). This model predicted one complete and one incomplete ␤-propeller for the
central and C-terminal domains, respectively, that comprise
the majority of vitronectin between amino acids 131 and 456.
The structure of the N-terminal somatomedin B domain (residues 1–51) could not be reliably modeled with the threading
algorithm. However, direct structural determinations using
NMR (5– 8) and x-ray crystallography (9) have elucidated the
structure of the somatomedin B domain. Although there is
some conflict among the structures that is rooted in the identification of disulfide bonds (6, 9 –13), in all of the structures on
the somatomedin B domain, the most important feature is a
single turn ␣-helix that defines the binding interface with
PAI-1. Small-angle x-ray scattering on monomeric vitronectin
generated a low resolution model that revealed a bi-lobed structure for vitronectin (14). Assembling the NMR and x-ray scattering data with the structure predicted from threading suggests that the C-terminal domain lies within a separate lobe
from the N-terminal somatomedin B domain (14).
PAI-1, the primary inhibitor of the plasminogen activators
uPA and tissue plasminogen activator belongs to the serine protease inhibitor (serpin) superfamily. PAI-1 shares the common
structural features and mechanism of inhibition characteristic
of the other inhibitory members of the serpin family (15, 16).
The tertiary structure of PAI-1 is composed of nine ␣-helices
(hA– hI), three ␤-sheets (A, B, and C), and a solvent-exposed
unstructured loop of ⬃20 amino acids referred to as the reactive center loop, because it carries the inhibitory reactive peptide bond. The overall scaffold of the molecule is defined by the

plasmon resonance; P1–P1⬘, Schecter and Berger nomenclature for the
reactive center loop residues of PAI-1, where P1, P2, P3, P4, . . . and P1⬘, P2⬘,
P3⬘, P4⬘, . . . denote those residues on the N-terminal and C-terminal sides
of the scissile bond, respectively; 5-IAF, 5-iodoacetamidofluorescein;
TMRIA, tetramethylrhodamine-5-iodoacetamide; PAI-1P1⬘-FL, PAI-1 labeled
at the P1⬘ residue with 5-IAF; PAI-1P1⬘-TMR, PAI-1 labeled at the P1⬘ residue
with TMRIA; GPI, glycosylphosphatidylinositol.
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five-stranded central ␤-sheet A. PAI-1 spontaneously alters in
conformation, converting from the active state to an energetically more favorable inactive latent state (16, 17, 19), where the
reactive center loop translocates into the central ␤-sheet.
The interaction between vitronectin and PAI-1 has important consequences for the regulation of cellular adhesion to the
extracellular matrix of the vasculature. Vitronectin binds a
number of integrins as well as the GPI-linked urokinase receptor, uPAR, at sites in the region of the somatomedin B domain.
When PAI-1 binds the somatomedin B domain of vitronectin, it
directly competes for binding with uPAR at an overlapping
binding site, thereby inhibiting uPAR-mediated cellular adhesion (20, 21). Integrin-mediated cellular attachment may also
be affected by PAI-1 binding to the somatomedin B domain,
presumably by blocking the RGD sequence (22), which is found
at residues 45– 47. PAI-1 has also been shown to detach cells by
disrupting the binding of integrin-uPAR complexes to
vitronectin, fibronectin, and collagen type-1 (23).
Because of the diverse roles of these proteins, investigating
the nature of PAI-1 binding to vitronectin has been an important area of research. Much effort has been focused on defining
the PAI-1-binding site within vitronectin. A large body of work
has characterized the somatomedin B domain of vitronectin as
the principal site of PAI-1 binding (21, 24 –26). The PAI-1binding site within the somatomedin B domain has been
restricted to amino acids 24 –30 using monoclonal antibodies
and mutagenesis (24). Recent crystallographic (9) and NMR
(5–7) structural studies have provided details about the PAI-1binding site in the somatomedin B domain in the vicinity of a
single-turn ␣-helix between residues 26 and 30. Conversely, the
complementary vitronectin binding site within PAI-1 has been
thoroughly investigated. A region between helices D, E, and F in
PAI-1 termed the flexible joint region was proposed to comprise
the primary binding site for vitronectin by Lawrence et al. (27) in
1994 and was finally fully mapped to this region by Jensen et al. (28)
in 2002. The epitope was later confirmed by x-ray crystallography
studies of the PAI-1-somatomedin B complex (9).
However, there is evidence that PAI-1 can bind to a region
other than the somatomedin B domain of vitronectin. Competition experiments using synthetic peptides or monoclonal
antibodies (29 –32) and cleavage of vitronectin with proteases
(33) have identified a PAI-1-binding site in the C-terminal
region of vitronectin or a site in the connecting region (34).
Studying vitronectin-PAI-1 complexes with analytical ultracentrifugation revealed a 2:1 PAI-1-vitronectin binding stoichiometry and the formation of higher order complexes at a PAI1-vitronectin ratio of 4:2 (32, 35). These reports of alternative
PAI-1-binding sites, coupled with the unusual stoichiometry of
the vitronectin-PAI-1 complex, have caused us to pursue a
deletion mutagenesis approach to address this problem. The
studies reported here were designed to evaluate directly
whether there is a second site for the binding of PAI-1 to
vitronectin that lies outside the well characterized N-terminal
site in the somatomedin B domain. A mutant form of vitronectin, r⌬sBVN, was engineered omitting the first 40 amino acids,
so that the mature peptide begins at lysine 41 upon secretion
and removal of the signal sequence. These experiments confirm
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a second PAI-1-binding site within vitronectin that lies outside
of the somatomedin B region.

EXPERIMENTAL PROCEDURES
Materials—Native vitronectin was purified from human
plasma using a modified protocol of the method developed by
Dahlback and Podack (36, 37). Multimeric vitronectin was prepared by denaturation of the protein in 8 M urea for 2 h at room
temperature followed by dialysis into PBS (140 mM NaCl, 3 mM
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4). Recombinant
human wild-type PAI-1 and recombinant stable PAI-1 mutant,
14-1B (38), used in the ELISA assays were both purchased from
Molecular Innovations, Inc. PAI-1 used in the Biacore experiments and latency transition assays was produced according to
the method outlined in Jensen et al. (28). The PAI-1 protein
preparations were tested for activity using a urokinase inhibition assay; all behaved similarly and fully inhibited urokinase.
The numbering used to denote the amino acid positions in
PAI-1 throughout the presented work is Ser1-Ala2-Val3-His4His5, according to Andreasen et al. (39). All other reagents were
of analytical reagent grade or better.
Cell Culture—Cultures of Spodoptera frugiperda (Sf9) or
Trichoplusnia ni (Hi5) cells (Invitrogen) were routinely grown
as monolayers in Corning Ti 75-cm2 culture flasks at 27 °C or as
suspension cultures in side-arm spinner flasks with gentle stirring at room temperature. Sf9 cells were grown in serum-free
Ex-Cell 420 medium, whereas Hi5 cells were grown in Ex-Cell
401 (both from J. R. H. Biosciences) without the addition of
serum. Rabbit smooth muscle cells (the kind gift of Dr. Daniel
Lawrence, University of Michigan) were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10%
fetal bovine serum. U937 cells (American Type Culture Collection) were grown in RPMI 1640 media supplemented with 10%
fetal bovine serum. U937 cells were stimulated for 24 h with 1
ng/ml human transforming growth factor ␤-1 (Sigma) and 50
nM 1␣25-dihydroxyvitamin D3 (Calbiochem) (40).
Generation of Recombinant Vitronectin—Both full-length
vitronectin and a deletion mutant of vitronectin lacking the first
40 amino acids were expressed in the baculovirus FastBac system (Invitrogen) as in the method described earlier (41). Both
constructs were subcloned into the pFastBac-1 vector (Invitrogen) and utilized the endogenous vitronectin signal sequence to
direct protein secretion. The deletion mutant, r⌬sBVN, was
generated using the following primers: ⌬sB sense, 5⬘-GGCTGTCGACAAGCCCCAAGTGACTCGCGG-3⬘ and ⌬sB antisense, 5⬘-GGGGCTTGTCGACAGCCAGAGCAACCCATG3⬘. The C termini of both recombinant vitronectin and r⌬sBVN
have an additional 28 amino acids, containing an myc epitope
and a 6⫻ histidine tag. The manufacturer’s guidelines were followed to transfect the insect cells for virus generation and subsequent protein expression. Both expressed recombinant
vitronectin (rVN) and r⌬sBVN were secreted into the medium,
and clarified spent medium was passed over Chelating Sepharose-Fast Flow resin (Amersham Biosciences). The column was
washed with binding buffer (5 mM imidazole, 0.5 M NaCl, 20 mM
Tris, pH 7.9) followed by wash buffer (60 mM imidazole, 0.5 M
NaCl, 20 mM Tris, pH 7.9). The bound protein was eluted with
elution buffer containing 1 M imidazole. Fractions were anaVOLUME 283 • NUMBER 16 • APRIL 18, 2008
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lyzed by Western blotting and Coomassie staining. Fractions
containing protein were pooled, dialyzed, and concentrated.
Protein concentration was determined as described previously
(41) by quantitative ELISA and the Pierce BCA Protein Assay.
The protein was also subjected to N-terminal protein sequencing, confirming the deletion of the somatomedin B domain as
well as cleavage of all but the last amino acid (valine) of the
signal sequence. Over the course of these studies, r⌬sBVN was
expressed from the initial viral stock multiple times. All
expressed protein was tested using PAI-1 and heparin binding
assays to confirm there was no significant preparation to preparation variability.
Heparin Binding Assays—A direct heparin binding assay was
used to measure vitronectin binding to heparin-coated microtiter plates as previously described (41). Briefly, wells were
coated with a 1 mg/ml solution of heparin (Sigma) then blocked
using 3% casein in PBS. The plates were incubated with serial
dilutions of native, multimeric, and recombinant vitronectin.
Bound vitronectin was detected using polyclonal antibodies to
vitronectin and peroxidase-labeled anti-rabbit secondary antibodies (Vector Laboratories). Kinetic analysis of the rate of
inactivation of thrombin by antithrombin in the presence of
heparin and the recombinant proteins was measured by continuously monitoring the cleavage of the chromogenic thrombin substrate Chromozym-TH (Roche Applied Science) over
time (42). Thrombin was diluted in reaction buffer (PBS with
0.1% polyethylene glycol 8000) to a concentration of 44 nM. A
final concentration of 45 nM antithrombin was used in the assay,
resulting in 70 – 80% inhibition of thrombin. Chromozym-TH and
heparin (average molecular weight, Mr 6000) were included in the
reaction at a final concentration of 0.19 nM and 0.9 g/ml, respectively. The reactions were monitored at 405 nm for 3 min at 30 °C
in 1-ml acrylic cuvettes (Sarstedt). The data were analyzed using
the IGOR software package (Wavemetrics) to determine the pseudo-first-order reaction rates.
Cell Adhesion Assays—Two different cell lines, from muscular and monocyte origin, were used to assess the effect of deleting the N-terminal of vitronectin on binding to integrins and
uPAR. Adherence of rabbit smooth muscle cells to recombinant vitronectin was determined by a method adapted from
Stefansson and Lawrence (22), who showed this interaction to
be primarily integrin-mediated. The wells of a 24-well tissue
culture plate were coated overnight at 4 °C with a 10 nM solution of vitronectin or recombinant vitronectin diluted in PBS.
After rinsing with PBS, the wells were blocked with 500 l of a
3.5% solution of BSA in PBS at room temperature for 1 h. Rabbit
smooth muscle cells were resuspended in serum-free medium
containing 1.5% BSA to a concentration of 75,000 cells/well and
allowed to adhere for 45 min. Bound cells were quantified by
measuring cell surface acid phosphatase. After rinsing the wells
to remove any unbound cells, 10 mg/ml p-nitrophenyl phosphate in 0.1 M sodium acetate, pH 5.0, was added to the wells.
The reaction was stopped after 1 h with the addition of an equal
volume of 1 M Tris, pH 9.0, and the absorbance was measured at
405 nm.
A human lymphoma cell line, U937, was also tested for
uPAR-mediated adhesion to wild-type vitronectin and
r⌬sBVN. For the U937 cell binding assay, 140 nM vitronectin or
APRIL 18, 2008 • VOLUME 283 • NUMBER 16

a recombinant vitronectin derivative was added to the wells of a
FluoroNunc plate with Maxisorb Surface microtiter plate
(Nunc) suitable for fluorescent applications. Wells were
blocked with a solution of 3% BSA in PBS. Stimulated U937 cells
were fluorescently labeled by uptake of 10 M calcein AM
(Molecular Probes) for 30 min. Cells were washed two times
with serum-free RPMI medium and resuspended at a concentration of 2 ⫻ 105 cells/well in serum-free RPMI plus 20 nM uPA
(Calbiochem). After an incubation of 1 h at 37 °C in 5% CO2, the
plate was rinsed with PBS to remove unbound cells. Cell binding was determined by measuring the fluorescence (ex 485/em
535) of the adhered cells in a Wallac Victor2 1420 Multilabel
Counter.
Integrin Binding Assay—Microtiter plates were coated with
100 l of a 2.5 g/ml solution of the integrin GPIIbIIIa in binding buffer (50 mM Tris, pH 7.4, 0.1 M NaCl, 1 mM MgCl2, 1 mM
CaCl2) according to the protocol described in a previous study
(43). Wells were blocked with 3.5% BSA in binding buffer for 1 h
at room temperature. Recombinant vitronectin was diluted to
500 nM in binding buffer plus 0.1% Tween and 0.2% BSA and
serially diluted down the plate. After incubating for 1 h at 37 °C,
the wells were rinsed and anti-vitronectin monoclonal antibody
(Quidel, 1:10,000) was added to the wells for 1 h at room temperature. Peroxidase-labeled anti-mouse secondary antibody
was added for 1 h at room temperature. The plates were developed using a 0.2 mg/ml solution of 2,2⬘-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt in 50 mM sodium
citrate, pH 5.5, containing 12 l of 30% H2O2. Absorbance was
read at 405 nm. All the following ELISA assays were developed
and read in the same manner.
uPAR Binding Assay—The binding of uPAR to recombinant
vitronectin was measured as described by Sidenius et al. (44)
with slight modification. The wells of a microtiter plate were
coated with multimeric vitronectin and recombinant vitronectin at a concentration of 15 nM in PBS. A 2:1 solution of uPAR (R
& D Systems) and uPA (Calbiochem) in PBS containing 0.1%
BSA and 0.1% Tween was mixed and allowed to incubate for 1 h
at room temperature. Vitronectin-coated wells were blocked
with 3% BSA in PBS, and the uPAR:uPA mixture (final concentration per well 60 and 30 nM, respectively) was added to the
wells. Following the 1-h incubation, a polyclonal anti-uPAR
antibody (Molecular Innovations) was added. The plate was
developed as described above.
PAI-1 Binding Assays—Competition experiments were used
to compare interactions between PAI-1 and native vitronectin
or the recombinant vitronectin samples, as described by Seiffert
and Loskutoff (25) with slight modification. Microtiter plates
were coated with a 1 g/ml solution of native vitronectin in PBS
overnight at 4 °C. Wells were blocked with 3% BSA in PBS for
1 h at 37 °C then washed. PBS containing 0.1% BSA and 0.1%
Tween 20 was used for the washes and for protein dilutions.
Vitronectin or recombinant vitronectin was serially diluted on
the plate following blocking. A constant concentration of either
wild-type or stable PAI-1 (0.4 nM) was added to the wells, and
the mixture was incubated at 37 °C for 2 h. The amount of
PAI-1 that bound to the immobilized vitronectin was detected
using polyclonal anti-PAI-1 antibodies.
JOURNAL OF BIOLOGICAL CHEMISTRY
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Analysis of PAI-1 Binding to r⌬sBVN by Surface Plasmon
Resonance—All SPR experiments were performed on a
BIACORE 3000TM instrument. Recombinant ⌬sBVN was coupled directly to the surface of a CM5TM chip by standard amine
coupling protocol by applying a 30 g/ml vitronectin, 10 mM
sodium acetate, pH 4.5, until a density of 600 response units
accumulated on the chip. Ethanolamine blocked empty flow
cells were used as a reference. When necessary, regeneration of
the flow cells between runs was achieved by injecting pulses of
10 mM glycine/HCl, pH 2.0, and/or 0.05% SDS in running buffer
until baseline levels were acquired. To determine the binding
affinity for PAI-1 binding to r⌬sBVN, 120-l samples of active
PAI-1 diluted in running buffer were injected in an array of
concentrations from 0.25 to 1500 nM at a flow rate of 30 l/min.
The equilibrium dissociation constant (KD) was calculated
according to the method outlined by Rich and Myszka (45). The
sensorgram responses at equilibrium were plotted against
PAI-1 concentration and fit by non-linear least squares to the
equation:
R⫽

R max共C/KD兲
1 ⫹ 共C/KD兲

(Eq. 1)

where R is the observed response, Rmax is the maximal response,
C is the analyte concentration, and KD is the equilibrium dissociation constant.
Analytical Ultracentrifugation—Sedimentation velocity
experiments were performed in a Beckman Optima XL-I ultracentrifuge with interference optics. For evaluating the effects of
increasing salt concentrations on the vitronectin-PAI-1 complexes, vitronectin and wild-type PAI-1 were mixed (3.2 M)
and dialyzed against PBS with varying concentrations of NaCl
(150, 250, and 500 mM). The samples were dialyzed for 2 h at
4 °C. The samples were allowed to equilibrate to room temperature before loading into the centerpieces. For the analytical
ultracentrifuge experiments using the 14-1B PAI-1 variant,
vitronectin, and 14-1B PAI-1 were dialyzed into PBS. Vitronectin and PAI-1 were mixed in a 1:1 molar ratio and incubated at
25 °C for 1 h. In both experiments, the samples were loaded
(400 l) into double-sector charcoal-filled Epon centerpieces.
Sedimentation velocity was performed at 50,000 rpm at 25 °C in
an An50 Ti eight-holed rotor. Interference scans were collected
at 1-min intervals. Analysis of sedimentation velocity data on
PAI-1-vitronectin complexes was performed using a Lamm
equation distribution model that calculates the concentration
of species of a given sedimentation coefficient (c(s)) with the
program Sedfit (46). c(s) distributions were calculated over a
range in sedimentation coefficients of 3–30, and an integration
tool was used to evaluate the amount of signal (total fringes)
corresponding to higher order PAI-1/vitronectin complexes (s
values between 14 and 26).
Fluorescence Resonance Energy Transfer Measurements—
FRET fluorescence measurements were made using a Varian
Cary Eclipse spectrofluorometer at 25 °C. Individual spectra
were collected in semi-micro quartz cuvettes (0.5 ⫻ 1.0 cm) as
averages of 5 emission scans using bandwidths of 5 nm and 10
nm for the excitation and emission beams, respectively. All
emission spectra were recorded with 0.1-s integration over a 1.0
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nm step resolution. For the 5-iodoacetamidofluorescein
(5-IAF) probe on the PAI-1P1⬘-FL variant, the excitation wavelength was 490 nm, and emission spectra were collected
between 500 and 700 nm. Energy transfer between the 5-IAF
probe on PAI-1P1⬘-FL and the tetramethylrhodamine-5-iodoacetamide (5-TMRIA) probe on PAI-1P1⬘-TMR was measured as
the decrease in donor fluorescence intensity, because the signal
obtained for the loss of donor fluorescence is typically greater
than the re-emitted fluorescence after subtraction of the appropriate control spectra. Donor-acceptor fluorescence (FD-A),
which corresponds to the fluorescence of the donor PAI-1P1⬘-FL
in the presence of acceptor PAI-1P1⬘-TMR, was measured as the
emission spectra of a 1:1 mixture of PAI-1P1⬘-FL (20 nM) and
PAI-1P1⬘-TMR (20 nM) after incubation with monomeric
vitronectin (20 nM). The raw fluorescence spectra were normalized for the contribution of non-FRET acceptor by subtraction
of spectra from equivalent binding experiments containing a
1:1 mixture of labeled acceptor and unlabeled donor (wild-type
PA1-1). The fluorescence of the donor probe only (FD) was
resolved by measuring the fluorescence of binding reactions
containing a 1:1 mixture of PAI-1P1⬘-FL and unlabeled wild-type
PAI-1 after incubation at 25 °C with monomeric vitronectin.
All fluorescence spectra for FRET measurements are averages
of two to four independent experimental acquisitions.
The efficiency of FRET (E) between the 5-IAF and 5-TMRIA
probes was calculated using the following expression (47, 48).
E⫽1⫺

FD ⫺ A
FD

(Eq. 2)

The distance between the two fluorophores coupled to PAI1P1⬘-FL and PAI-1P1⬘-TMR, which participate in FRET, is then
described by Equation 3,
R⫽

冉 冊
1
⫺1
E

1/6

R0

(Eq. 3)

where R is the distance between the donor and acceptor
probes, Ro is the distance at which there is a 50% transfer of
the fluorescence energy from the donor probe to the acceptor probe, and E is the FRET efficiency defined by Equation 2,
above (47, 48). The value of Ro is defined by the expression in
Equation 4 (48, 49),
R 0 ⫽ 9.787 ⫻ 10 3 共  2 n ⫺4D JDA兲1/6

(Eq. 4)

and is such that it is dependent on 2, the orientation factor,
which is routinely given a value of 2/3 indicating that both
donor and acceptor fluorophores exhibit isotropic motion (47–
49), n the experimentally determined refractive index of 1.3364
(using a Carl Zeiss ABBE-type refractometer), D the experimental quantum yield of the donor fluorophore, and JDA the
overlap integral for the donor and acceptor fluorophore pair,
which was previously determined to be 3.06 ⫻ 10⫺13 M⫺1 cm3
(49). The quantum yield was measured by comparison of the
emission spectrum of PAI-1P1⬘-FL to that of a fluorescein
reference in 0.1 M NaOH ( ⫽ 0.95) and evaluated as 0.143 by
Equation 5,
VOLUME 283 • NUMBER 16 • APRIL 18, 2008
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Q D ⫽ QR

ID ODR nD2
IR ODD n2R

(Eq. 5)

where QD and QR are the quantum yields of the donor and
reference, respectively, ID and IR are the respective integrated
fluorescence emission intensities over the 500 to 600 nm spectrum, ODD and ODR are the optical densities at the excitation
wavelength of 490 nm, and the values n2D and n2R represent the
refractive indices (determined as 1.3364 for both donor and
reference samples).

RESULTS
A deletion mutant of vitronectin, r⌬sBVN, was constructed
to evaluate whether there is a second site for the binding of
PAI-1 in vitronectin, which lies outside the well characterized
N-terminal site in the somatomedin B domain. The first 40
amino acids of vitronectin were deleted, removing essentially
all of the well structured disulfide cross-linked fold of the
somatomedin B domain (typically delimited as residues 1– 44),
but retaining the RGD integrin-binding sequence found within
a more flexible region at residues 45– 47. The recombinant protein was produced using the baculovirus expression system as
previously described (41). N-terminal sequencing confirmed
the absence of the somatomedin B domain and cleavage of all
but the final amino acid of the native signal sequence (valine).
Gel-filtration chromatography of r⌬sBVN showed that it was
oligomeric (data not shown), as observed previously with
recombinant full-length and C-terminal truncated vitronectin
expressed without a tag in the baculovirus system (41). The
presence of the His6 tag had no effect on oligomerization,
because r⌬sBVN expressed without the tag was also oligomeric
(data not shown). Therefore, in assessing the functions of
r⌬sBVN, the deletion mutant was compared both to multimeric and monomeric plasma vitronectin.
Heparin Binding Activity of the Deletion Mutant Is Comparable to That of Multimeric Vitronectin—As a first step, the
recombinant proteins were tested for the ability to bind heparin. The results shown in Fig. 1A demonstrate that the recombinant vitronectin and r⌬sBVN bound equally well to immobilized heparin in a solid-phase binding assay. Binding of both the
recombinant forms of vitronectin is similar to that of multimeric and much greater than that of native vitronectin, demonstrating the increased binding of the multimeric forms of
vitronectin to heparin. This difference in the heparin-binding
ability of monomeric and multimeric vitronectin has been
attributed to the multivalent binding capacity of the multimeric
form of vitronectin (50, 51).
A solution-phase heparin neutralization assay was also performed to compare the heparin binding ability of the recombinant proteins. This assay measures the activity of thrombin in
the presence of its inhibitor (antithrombin) and heparin (41,
42). Heparin acts as a catalyst in the reaction, bringing thrombin and antithrombin together more rapidly, resulting in
increased inhibition of thrombin. When vitronectin is added to
the mixture, it competes with both thrombin and antithrombin
for heparin binding, reducing the rate of interaction between
thrombin and antithrombin (the Kapp). The effects of adding
varying concentrations of native vitronectin and recombinant
APRIL 18, 2008 • VOLUME 283 • NUMBER 16

FIGURE 1. Recombinant forms of vitronectin bind to heparin. In a direct
heparin-binding assay (A), a fixed concentration of heparin was immobilized
in microtiter wells and blocked with casein. Varying concentrations of rVN (Œ),
r⌬sBVN (䡺), native vitronectin (⽧), and multimeric vitronectin (E) were incubated in the heparin-bound wells for 1 h. After rinsing the wells, bound
vitronectin was detected using polyclonal anti-vitronectin antibodies and a
peroxidase-labeled secondary antibody. Neutralization of the anticoagulant
activity of heparin is followed in B. Heparin activity was measured by a
decrease in thrombin activity due to inhibition by antithrombin. Thrombin
activity was continuously monitored over time by measuring the hydrolysis
of the chromogenic substrate Chromozym-TH. Variations in the Kapp were
measured at various concentrations of vitronectin. Kapp rates were determined using the IGOR pro software and fitting the data using least-squares
analysis. Kapp values were standardized to the reaction rate of heparin-catalyzed inhibition in the absence of vitronectin. Data points are shown at varying concentrations of multimeric vitronectin (E), rVN (Œ), and r⌬sBVN (䡺).

vitronectin are shown in Fig. 1B. The concentrations of rVN
and r⌬sBVN needed to inhibit heparin activity by 50% were
0.04 and 0.2 M, respectively. The corresponding value for multimeric vitronectin was 0.16 M, consistent with previous
measurements using this assay (41, 50). The Kapp of 0.04 M for
rVN was comparable to other recombinant forms of vitronectin
previously expressed in the baculovirus system, which demonstrated 50% inhibition at 0.05 M (41). The Kapp of the multimeric forms of vitronectin are all tighter than that of monomeric
vitronectin with a Kapp of 0.6 M (50). The results of the solidphase and solution-phase heparin binding assays indicate that
both rVN and r⌬sBVN bind heparin with the same high valency
interaction characteristic of the multimeric form of vitronectin.
JOURNAL OF BIOLOGICAL CHEMISTRY
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bound GPIIbIIIa efficiently over a
wide concentration range. Fig. 2B
shows the results of the cell adhesion assay. Rabbit smooth muscle
cells were allowed to attach to wells
coated with equal molar concentrations of immobilized multimeric
vitronectin, rVN, or r⌬sBVN. After
thoroughly washing the unbound
cells from the wells, substrate was
added to detect the number of
bound cells using acid phosphatase
as a surface marker. The cells bound
equally well to rVN, r⌬sBVN, and
multimeric vitronectin. Taken
together, these results demonstrate
that the RGD site of r⌬sBVN is
exposed and available for integrin
binding.
Recombinant Vitronectin Lacking
the Somatomedin B Domain Does
Not Bind to uPAR—The adhesive
functions of vitronectin are attributed not only to integrin binding but
FIGURE 2. Recombinant ⌬sBVN binds integrins, but not uPAR. The recombinant ⌬sBVN bound to immobi- also to interactions with the GPIlized integrin GPIIbIIIa (A) and supported the binding of rabbit smooth muscle cells (B). A, varying concentra- linked urokinase receptor, uPAR.
tions of recombinant vitronectin (Œ) and recombinant ⌬sBVN (䡺) were incubated for 1 h in GPIIbIIIa-coated
wells. Wells were washed, and bound vitronectin was detected using a monoclonal anti-vitronectin antibody Because binding sites for PAI-1 and
and a peroxidase-labeled secondary antibody. The binding of rabbit smooth muscle cells to vitronectin is uPAR extensively overlap in the
shown in B. Equal molar amounts (8 nM) of multimeric vitronectin (solid bar), rVN (open bar), and r⌬sBVN
(shaded bar) were immobilized in the wells of a tissue culture plate. Following blocking of the wells with a N-terminal domain, the deletion
solution of 3.5% BSA in PBS, rabbit smooth muscle cells were added and allowed to adhere for 1 h. The amount mutant likely eliminates vitronectin
of cell binding was determined by following the conversion of -nitrophenyl phosphate to -nitrophenol by binding to this receptor. Again, this
alkaline phosphatase on the cell at an absorbance of 405 nm. The binding of smooth muscle cells to blocked
wells alone was negligible and was subtracted as background. The recombinant ⌬sBVN does not bind to activity was tested with purified
soluble uPAR (C) or support U937 cell binding (D). C, an equal molar concentration of multimeric vitronectin receptors and intact cells. Testing
(solid bar), r⌬sBVN (open bar), or rVN (shaded bar) was used to coat the wells of a microtiter plate. The wells were the binding of vitronectin to puriblocked with 3% BSA in PBS before incubation with soluble uPAR. The amount of bound uPAR after washing
was determined using polyclonal anti-uPAR antibodies and a peroxidase-labeled secondary antibody. D, stim- fied soluble uPAR (Fig. 2C), multimulated U937 cells were stained with calcein, resuspended in serum-free medium with 15 nM uPA, and added to eric and recombinant full-length
the wells of a microtiter plate that had been coated with equal molar concentrations of multimeric vitronectin
(solid bar), r⌬sBVN (open bar), or rVN (shaded bar). Cell binding was determined by measuring the fluorescent vitronectin bound to uPAR equally
intensity of the calcein-labeled cells after washing with PBS. U937 cell binding to BSA-blocked wells accounted whereas r⌬sBVN binding was neglifor 4% (⬃850,000 units) of the binding to multimeric vitronectin and was subtracted as background. In both gible. The results using purified
panels, the percent binding was calculated relative to multimeric vitronectin.
uPAR corroborate the findings with
U937 cells. U937 cells adhered to
The Recombinant Vitronectin, r⌬sBVN, Binds Integrins—To vitronectin upon activation at which time uPAR was expressed
further address the functionality of r⌬sBVN, the ability of the and localized to the cell membrane. The cell binding data in Fig. 2D
protein to bind integrins and support cell adhesion was tested. show that activated U937 cells adhered strongly to both multimThe deletion mutant, r⌬sBVN, was designed to ablate the eric vitronectin (solid bar) and rVN (shaded bar). However, there
N-terminal PAI-1-binding site, while leaving intact the inte- was essentially no binding of the U937 cells to r⌬sBVN.
Wild-type and Stable PAI-1 Exhibit Differences in Binding to
grin-binding RGD sequence between residues 45 and 47.
Whereas some adhesive proteins, such as fibronectin, contain r⌬sBVN—The results presented thus far demonstrate the suitsecondary integrin binding sites, it has been shown that the ability of using a truncated vitronectin expressed using the
RGD sequence is the mediator of integrin binding to vitronec- baculovirus system to study the function of the somatomedin B
domain. One prominent goal of this project was to investigate
tin (52).
To test the binding of integrins to the recombinant vitronec- the PAI-1-binding ability of r⌬sBVN. A competitive binding
tins, a solid-phase assay using purified integrins was performed assay was used in which varying concentrations of native
(Fig. 2A). The integrin used in this assay was GPIIbIIIa, which is vitronectin, multimeric vitronectin, rVN, and r⌬sBVN were
known to mediate the binding of activated platelets to vitronec- incubated with a fixed concentration of PAI-1; competition for
tin (53). Varied concentrations of the recombinant proteins binding of PAI-1 to solid-phase monomeric vitronectin was
were incubated with immobilized GPIIbIIIa, and the amount of measured. Fig. 3A clearly shows binding of wild-type PAI-1 to
bound vitronectin was measured. Both rVN and r⌬sBVN r⌬sBVN. Native and multimeric vitronectin as well as rVN
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FIGURE 3. The recombinant ⌬sBVN retains PAI-1-binding activity. Equal
molar concentrations of native vitronectin (⽧), multimeric vitronectin (E),
rVN (Œ), and r⌬sBVN (䡺) were tested for binding to wild-type PAI-1 (A) or the
14-1B mutant form of PAI-1 (B) in a competitive assay where native vitronectin is immobilized in the wells of a microtiter plate. A fixed concentration of
PAI-1 was added to wells in the presence of increasing concentrations of
competing vitronectin. Bound PAI-1 was detected using a polyclonal antiPAI-1 antibody. Percent binding inhibition was calculated using the equation,
[(Ax ⫺ A0)/A0]*100, where A0 is the absorbance in the absence of competing
vitronectin, and Ax is the absorbance at a given concentration of vitronectin.

effectively compete for wild-type PAI-1 binding, almost completely inhibiting PAI-1 binding to immobilized vitronectin.
A different vitronectin-binding behavior is observed with the
stable PAI-1 mutant, 14-1B, compared with wild-type PAI-1 in
the competitive binding assay. A unique property of PAI-1
among other serpins is its propensity to convert to a latent,
inactive form that can no longer inhibit plasminogen activators.
The binding of vitronectin to PAI-1 decreases the rate at which
PAI-1 converts to this latent form. Stable forms of PAI-1 that do
not collapse to the latent form at an appreciable rate have been
engineered by incorporating amino acid replacements at a variety of loci, including the core ␤-sheet (16, 27, 38, 54, 55). The
stable variant of PAI-1 that has been best characterized and has
yielded the crystallographic structure of active PAI-1 (55) is the
14-1B mutant with the mutations N152H, K156T, Q321L, and
APRIL 18, 2008 • VOLUME 283 • NUMBER 16

FIGURE 4. PAI-1 binds to the second site on vitronectin with lower affinity
than the SMB domain. Representative sensorgrams obtained from the injection of varying concentrations of PAI-1 (1, 5, 10, 25, 50, 75, 250, and 500 nM)
over immobilized r⌬sBVN in a BIACORE 3000TM are shown in A. A duplicate
series of sensorgram responses were normalized and plotted versus PAI-1
concentration (B). The points were fit to the 1:1 interaction model (Equation 1)
to yield the KD of 29 ⫾ 3 nM with an R2 value of 0.997.

M356I (16, 38). Although most functions are indistinguishable
for wild-type and the stable 14-1B PAI-1, recent work suggests
that there are subtle differences in structure and function (35,
56). For this reason, the stable 14-1B variant was compared with
native PAI-1 in binding of full-length vitronectin and the deletion mutant, r⌬sBVN. The results of the competitive PAI-1
binding using stable 14-1B PAI-1 are shown in Fig. 3B. Multimeric vitronectin, native vitronectin, and rVN inhibit the binding
of stable PAI-1 to immobilized monomeric vitronectin. However, r⌬sBVN is an ineffective competitor for PAI-1 binding in
this assay, indicating a difference in affinity for 14-1B versus
wild-type PAI-1 binding to r⌬sBVN.
Affinity of Binding at the Secondary Site Is Measured by Equilibrium Analysis Using SPR—Initial SPR experiments confirmed the competitive PAI-1 binding ELISA data, showing
binding of wild-type PAI-1 to r⌬sBVN. To determine the equilibrium dissociation constant for PAI-1 binding to the second
site of vitronectin only, varying concentrations of PAI-1 were
injected across the captured r⌬sBVN to produce the sensorgrams shown in Fig. 4A. The responses from the PAI-1 injecJOURNAL OF BIOLOGICAL CHEMISTRY
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tions were concentration-dependent, and all reached equilibrium within ⬃1 min. To extract a binding constant for this
interaction, the responses at equilibrium were plotted against
PAI-1 concentration (Fig. 4B). The data were fit to a simple 1:1
binding isotherm (Equation 1) and yielded a KD of 29 ⫾ 3 nM.
Measurement of FRET between Differentially Labeled PAI-1
Molecules Indicates Binding to Two Sites on the Surface of
Monomeric Vitronectin—Whereas the structure of a recombinant somatomedin B domain bound to PAI-1 has been solved,
there are as yet no available experimental structures describing
the relative orientation of the second PAI-1-binding site relative to the primary site in the somatomedin B domain within
full-length vitronectin. Small-angle x-ray scattering shows that
the C-terminal domain of vitronectin lies within a separate lobe
from the N-terminal somatomedin B domain (14). FRET was
chosen as a reasonable approach to test the relative proximity of
the PAI-1-binding sites within the bi-lobed structure. For this
approach, we reasoned that placement of the donor and acceptor
fluorophores on the P1⬘ residue of the reactive center loop of
PAI-1 would create a labeled variant that is known to be fully active
(57) and yet provides the best arrangement in which the tethered
probe will remain solvent-exposed and free from interactions with
the bound vitronectin (58). To this end, we engineered a derivatizable cysteine residue at the P1⬘ position of the reactive center
loop (M349C) and labeled the resulting PAI-1 variant with either
5-IAF or 5-TMRIA to act as a fluorescence donors (PAI-1P1-FL) or
acceptors (PAI-1P1⬘-TMR), respectively.
Equal amounts of PAI-1P1-FL and PAI-1P1⬘-TMR were incubated with monomeric vitronectin at the requisite 2:1 ratio of
PAI-1-vitronectin to ensure the formation of complexes in the
sample that have both the high affinity and low affinity binding
sites on vitronectin saturated, because conditions favoring formation of complexes that are not saturated at both sites would
effectively decrease the concentration of available FRET pairs.
Reaction mixtures were incubated at 25 °C for at least 5 min
prior to initiating the acquisition of spectra to allow the formation of complexes to proceed to completion, based on our
measured rates above. The observation of FRET between molecules of PAI-1P1⬘-FL and PAI-1P1⬘-TMR is evident from comparison of the fluorescence emission spectra obtained in the presence and absence of the acceptor PAI-1P1⬘-TMR, which
demonstrated a 19.3% quench in donor fluorescence in the
presence of acceptor (Fig. 5). Total donor-acceptor fluorescence (FD-A) and donor only fluorescence (FD) were calculated
from integrations of the total peak fluorescence between 500
and 700 nm for each respective spectrum and subsequent evaluation of Equation 2 indicated an efficiency of energy transfer
of 0.19 for the PAI-1P1⬘-FL/PAI-1P1⬘-TMR FRET pair co-localized
on the surface of monomeric vitronectin. A calculated Ro of 45
Å for this donor and acceptor pair was determined from Equation 4 using an experimentally determined quantum yield of
0.143 for the PAI-1P1⬘-FL donor (Equation 5). The standard
assumption that both the donor and acceptor probes exhibited
isotropic motion was invoked, and therefore a value of 2/3 was
valid for the orientation factor 2 (47– 49). This value, in combination with the above determination for the efficiency of
FRET, was used to calculate the intermolecular distance
between the fluorescence labels on PAI-1P1⬘-FL and PAI-1P1⬘-TMR
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FIGURE 5. FRET reveals the co-localization of two PAI-1 molecules on
plasma vitronectin. Fluorescence donor PAI-1P1⬘-FL (20 nM) was reacted with
vitronectin (20 nM) in the presence of “cold” wild-type PAI-1 (20 nM, dashed
line) or with acceptor PAI-1P1⬘-TMR (20 nM, solid line) to yield a final 2:1 ratio
(PAI-1-vitronectin). Emission spectra were recorded following excitation at
490 nM and corrected for dilution and the contribution of residual acceptor
PAI-1P1⬘-TMR fluorescence when excited at 490 nM.

when in a complex with monomeric vitronectin by evaluation
of Equation 3, yielding a calculated distance of 57 Å.
Under the conditions of this experimental design (i.e. a 1:1
ratio of donor and acceptor fluorophores) and assuming two
binding sites for PAI-1 on vitronectin, the statistical expectation is that only 50% of the binding events will have resulted in
productive donor-acceptor FRET pairs. The remaining 50% of
the binding events will presumably be equally distributed
between donor-donor and acceptor-acceptor pairs. Whereas
any acceptor-acceptor pairs would have a negligible contribution to the recorded fluorescence spectra, a donor-donor pair of
PAI-1P1⬘-FL/PAI-1P1⬘-FL will result in fluorescence quenching
due to homo-FRET between the two 5-IAF probes on account
of the small Stokes shift found with the fluorescein fluorophore.
The net result would be a reduction in the integrated intensity
of the observed fluorescence spectra. Nonetheless, the magnitude of this effect on the spectra obtained in the presence and
absence of acceptor, as well as the calculated values for FD-A and
FD, should be equivalent for both conditions using this experimental design. Therefore, homo-FRET should not have any significant influence on the calculated intermolecular distance
between donor and acceptor probes, because the calculation of
energy transfer efficiency (Equation 2), which is used in the
distance evaluation of Equation 3, is dependent on the relative
ratio of FD-A/FD fluorescence.
Ionic Interactions Mediate the Secondary Vitronectin-PAI-1
Interaction—Analytical ultracentrifugation was performed to
evaluate conditions favorable for formation of higher order
PAI-1-vitronectin complexes. These experiments were adapted
from the published analyses using sedimentation velocity
experiments, which demonstrate that binding of PAI-1 in a 2:1
stoichiometry promotes association to higher order forms (35).
VOLUME 283 • NUMBER 16 • APRIL 18, 2008
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FIGURE 6. Sedimentation velocity analysis of equimolar mixtures of
vitronectin and PAI-1 at varying NaCl concentrations. Mixtures of 3.2 M
vitronectin and PAI-1 were evaluated by analytical ultracentrifugation using
the sedimentation velocity method. Data were analyzed using the c(s)
method using SEDFIT (46). Plots showing the distribution of species in each
sample in the range of sedimentation coefficients from 4 to 10 S are shown for
samples in 20 mM sodium phosphate containing 150 mM (solid line), 250 mM
(hatched line), and 500 mM (dashed line) NaCl.

The analyses of the data utilize a global fit to all scans taken
during the course of the sedimentation velocity experiment and
are plotted as a c(s) function (35, 46, 59), which is the distribution of species over a range of sedimentation coefficients, showing the concentration of the individual species. Thus, the binding of PAI-1 to both the somatomedin B domain and the
secondary site appears to be required for higher order associations to ensue. For this study, sedimentation velocity experiments were conducted using varying concentrations of NaCl
(Fig. 6). Equimolar mixtures of vitronectin and PAI-1 at a physiological salt concentration (150 mM) form a 2:1 PAI-1vitronectin complex (⬃6.5 S (35)). Raising the NaCl concentration favors the formation of 1:1 PAI-1-vitronectin complexes.
At the highest salt concentration (500 mM), the PAI-1 and
vitronectin complexes were solely 1:1 (⬃5.5 S), whereas the 250
mM sample was a mixture of 1:1 and 2:1 PAI-1-vitronectin complexes. The sensitivity of the observed formation of higher
order complexes indicates that occupancy of the second site on
vitronectin is dependent on charge-charge interactions
between vitronectin and PAI-1.
Active PAI-1 and the 14-1B Mutant Differ in Their Ability to
Form Higher Order Complexes—Using a different approach, an
evaluation was made of the need for occupation of both the
somatomedin B domain and secondary site with PAI-1 for association to higher order complexes. Recalling that our binding
assays show a weaker affinity of the r⌬sBVN for the stable 14-1B
PAI-1 mutant (Fig. 3B), it was reasoned that higher order complexes would form to a lesser extent upon binding to the stable
mutant. The 14-1B mutant has been commonly used to mimic
wild-type PAI-1, although there is accumulating evidence that
the 14-1B mutant does not altogether recapitulate the structure
and function of wild-type PAI-1 (56). Once again, sedimentation velocity analysis was used. Fig. 7A shows a typical analysis
of the sedimentation equilibrium data on a mixture of vitronecAPRIL 18, 2008 • VOLUME 283 • NUMBER 16

FIGURE 7. Analytical ultracentrifugation experiments demonstrate differences in higher order species formed by vitronectin with wild-type PAI-1
versus 14-1B PAI-1 variant. Mixtures of vitronectin (0.5 mg/ml) in a 1:1 molar
ratio with wild-type PAI-1 or 14-1B PAI-1 were analyzed by sedimentation velocity (50,000 rpm) in a Beckman XL-I analytical ultracentrifuge. Data were analyzed
using a continuous c(s) distribution model with the program SEDFIT (46). A, continuous c(s) distribution of complexes formed upon mixing of vitronectin with
wild-type PAI-1. B, distribution profiles of higher order species formed between
vitronectin and wild-type (solid line) or 14-1B stable mutant PAI-1 (dotted line).
C, bar graph comparing the relative amounts of higher order species (s ⫽ 14 –26)
formed when vitronectin is mixed with either wild-type or 14-1B PAI-1. Peaks in
the c(s) distribution in s ⫽ 14 –26 range were integrated, and results were normalized relative to the total amount of protein loaded (concentrations are given in
fringes). Error bars represent root mean square deviation values normalized to
total loading concentration (fringes).
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tin and wild-type PAI-1 using the continuous c(s) method to
display the multiple species in the mixture (35, 46, 59). Consistently with our previous work (35), it is apparent from these
data that wild-type PAI-1 promotes the formation of higher
order complexes in addition to stoichiometric 1:1 and 1:2
vitronectin-PAI-1 complexes (35). Continuous c(s) distributions for mixtures of vitronectin with wild-type PAI-1 or the
variant 14-1B in the region of s-values corresponding to these
higher order species are shown in Fig. 7B. From this comparison, it is clear that the higher order species are more abundant
in mixtures containing the native form of PAI-1 rather than the
14-1B mutant. The increase in species with s-values between 14
and 26 for both forms of PAI-1 is quantified in Fig. 7C. Not only
is there a lower total concentration of these higher order complexes with the stable mutant form, but also the relative distribution across the range in s values is skewed so that there are
diminishing amounts of complexes at higher s values with the
stable mutant versus native PAI-1 (Fig. 7B).

DISCUSSION
A Mutant Form of Vitronectin Lacking the Somatomedin B
Domain Exhibits Normal Heparin- and Cell-binding Functions—
Prokaryotic expression systems have been used extensively
in the study of vitronectin function (9, 26, 60 – 62). The lack
of post-translational modifications is one of the potential
drawbacks in using these systems, especially with a protein
like vitronectin that has numerous post-translational modifications, including disulfide bonds. The baculovirus system
was chosen for expression of the vitronectin deletion mutant
lacking the somatomedin B domain, because this system has
been used successfully to express vitronectin (41, 52, 63, 64).
Characterization of full-length vitronectin produced by the
baculovirus cells determined it to be functionally similar to
multimeric vitronectin (41). Significantly, the recombinant
protein reacts with conformation-specific monoclonal antibodies and is generally considered to be a reasonable mimic
of the form of vitronectin found in the extracellular matrix
(41, 65, 66).
r⌬sBVN was compared with monomeric and multimeric
vitronectin using functional assays that span a broad range of
activities. Based on the findings in two independent assays,
there were no significant differences in the ability of
r⌬sBVN, rVN, and multimeric vitronectin to bind heparin.
The RGD sequence important for integrin binding was
accessible in the r⌬sBVN, as concluded by the cell binding
and integrin binding assays. For the cell binding assay, there
was no appreciable difference observed for any of the
vitronectin samples. Therefore, the determinants necessary
to promote cellular adhesion are contained outside the
somatomedin B domain and are accessible even in an oligomeric state. The integrin binding ability of the recombinant
proteins was also investigated using an established vitronectin binding integrin, GPIIbIIIa (also referred to as ␣IIb␤3).
This integrin, expressed on the surface of platelets, binds
vitronectin and facilitates their adhesion to sites of injury
during thrombus formation (67). Both of the recombinant
proteins, rVN and r⌬sBVN, exhibited similar binding to
immobilized GPIIbIIIa. The results of these experiments
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indicate that the cell binding sequence (RGD) necessary for
integrin adhesion is exposed in both r⌬sBVN and rVN.
Cells attach to vitronectin in the extracellular matrix via their
interactions with not only integrins but with uPAR as well. The
binding of uPA to uPAR causes a conformational change in
uPAR that increases its affinity for vitronectin (68). Because
uPA is responsible for the generation of plasmin, this system is
important in controlling extracellular proteolysis and cellular
adhesion. The uPAR-binding site within vitronectin has been
localized to the somatomedin B domain (21, 26, 69). Our results
support this conclusion. There was no significant binding of
either purified uPAR or activated U937 cells to r⌬sBVN lacking
the somatomedin B domain.
The Mutant Form of Vitronectin Missing the Somatomedin
B Domain Exhibits Residual PAI-1 Binding—A high affinity
binding site for PAI-1 has been localized to the somatomedin
B domain. However, there are numerous reports that allude
to PAI-1-binding sites in the connecting region (34, 70) or
the heparin-binding domain (29 –31, 33). These studies coupled with results from our laboratory that show two PAI-1
molecules will bind to one vitronectin molecule (32, 35) suggest there is a second PAI-1-binding site in vitronectin outside of the somatomedin B domain. By using a deletion
mutant of vitronectin lacking the high affinity PAI-1-binding site, the somatomedin B domain, we were able to address
the issue more directly. The result from a competitive PAI-1
binding assay (Fig. 3A) clearly demonstrates that wild-type
PAI-1 binds r⌬sBVN, because the r⌬sBVN deletion mutant
competes with native plasma vitronectin for binding to wildtype PAI-1. At saturating concentrations, the r⌬sBVN deletion mutant inhibits binding of PAI-1 to full-length vitronectin by roughly 50%, consistent with PAI-1 binding to only
one of two sites that is retained in the deletion mutant. The
interaction between active wild-type PAI-1 and r⌬sBVN is
appreciable, as evidenced by a KD of 30 nM (⬃2 orders of
magnitude less than full-length vitronectin with the somatomedin B domain intact, which is ⬃0.3 nM (26, 71–74)). The
deletion mutant is multimeric; therefore, avidity may affect
the PAI-1 binding and the KD may appear tighter due to
multivalent display of these secondary PAI-1-binding sites.
(The effect of multimeric vitronectin yielding apparent
tighter binding to heparin has been attributed to this effect
(51).)
The observation of two separable binding sites on
vitronectin and PAI-1 was further substantiated by the use of
FRET to demonstrate the binding to two molecules of PAI-1
at different binding sites on vitronectin. For this experiment,
PAI-1 molecules were labeled with separate fluorophores
that can serve as a donor and acceptor and the labeled PAI-1
molecules were mixed with vitronectin to test for FRET,
which is distance-dependent and will occur if two PAI-1 are
bound to the same molecule of vitronectin. These experiments were performed at concentrations of vitronectin and
PAI-1 that are well below those that lead to assembly into
higher order complexes to prevent any possibility that FRET
could be attributed to intermolecular association and formation of a multimeric vitronectin scaffold to which PAI-1 is
bound. Fluorescence measurements on the complexes demVOLUME 283 • NUMBER 16 • APRIL 18, 2008
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onstrated energy transfer, and the FRET signal was
concentration-dependent, so that increasing the ratio of
vitronectin to PAI-1 decreased the FRET signal, in effect
sequestering PAI-1 on separate vitronectin molecules by
binding to the high affinity site in the somatomedin B
domain. The FRET measurements indicate the binding sites
to be separated by ⬃57 Å on the surface of vitronectin, which
has an ellipsoid shape with a length of ⬃110 Å (14).
Stable PAI-1 (14-1B) Displays an Altered Affinity Compared
with Wild-type PAI-1 for the Somatomedin B Deletion Mutant—
The proposal of two binding sites for PAI-1 on vitronectin
has been controversial. Our original work in the ultracentrifuge that demonstrated a 2:1 stoichiometry for the PAI-1vitronectin complex also contained data using two different
monoclonal antibodies, mAB153 and mAB8E6, where each
inhibited binding to vitronectin only by ⬃50% (32). This
result provided some of our first evidence for two sites,
which were recognized as separate epitopes by the two
monoclonal antibodies (32). However, this interpretation
has been questioned by others who instead observed full
inhibition of binding using either of the two antibodies; their
suggestion involved mAB8E6 exerting steric effects that perturb the primary site in the somatomedin B domain, rather
than defining a second PAI-1-binding site on vitronectin
(26). However, these contrary experiments used different
reagents than the ones we have employed in this study. Notably, the other experiments used denatured vitronectin, along
with the stable mutant of PAI-1 (14-1B) (16, 38), which is
often used by experimentalists and deemed to be equivalent
to wild-type PAI-1. As seen in Figs. 3 and 7 our experiments
have established differences in the binding affinities of the
14-1B stable mutant to the separate PAI-1-binding sites
within vitronectin as evidenced in the competitive PAI-1
binding assay using vitronectin and r⌬sBVN where fulllength vitronectin binds 14-1B PAI-1 and the somatomedin
B deletion mutant binds very weakly to 14-1B PAI-1. These
results using this stable PAI-1 mutant suggest that it is the
negligible affinity of 14-1B for the second site on vitronectin,
outside of the somatomedin B domain, that accounts for the
inconsistent results with antibodies noted in the experiment
above.
These findings add to accumulating evidence that the well
characterized 14-1B stable mutant of PAI-1 does not altogether
recapitulate the structure and function of wild-type PAI-1. The
differences noted between wild-type PAI-1 and the 14-1B
mutant may be based on structural differences. In an elegant
study that was recently published using donor-donor energy
migration and dimer formation by BODIPY fluorophores, the
reactive center loop of PAI-1 in solution was shown to be
closely associated with the central ␤-sheet or partially inserted
into ␤-sheet A rather than extended as suggested in crystallographic studies using the 14-1B mutant (56). The different conformations of the wild-type and the 14-1B stable PAI-1 mutant
may be responsible for the differences in binding events
described above and in the reported PAI-1 binding abilities in
the literature.
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Two Binding Sites on Vitronectin Support Stepwise Binding
and Assembly of Complexes—Over the last several years, work
from our laboratory has addressed the hypothesis that higher
order PAI-1-vitronectin complexes form in a stepwise and
concentration-dependent fashion via 1:1 and 2:1 intermediates,
with the 2:1 complex serving a key role in assembly of higher
order complexes. A variety of approaches has been used to test
this idea, including sedimentation velocity experiments in the
analytical ultracentrifuge that suggested that PAI-1 and
vitronectin assemble into higher order forms via an ordered
pathway that is triggered upon saturation of the two PAI-1binding sites of vitronectin to form the 2:1 complex (35). This
2:1 PAI-1-vitronectin complex appeared to be an obligatory
intermediate in the assembly of higher order complexes. The
demonstration that 14-1B PAI-1 exhibits weaker binding to the
second site that lies outside the somatomedin B domain agrees
with this model, because this mutant promotes association to
higher order complexes to a lesser extent compared with wildtype PAI-1.
The present work, which substantiates the idea of a second-PAI-1-binding site in vitronectin, suggests that a complementary second site should reside in PAI-1. Other work
from our laboratory extends these results and defines the
complementary binding site within PAI-1, a necessary feature that must exist for an ordered mechanism of binding
and assembly of higher order complexes to be operable.3
Furthermore, we have used use pre-steady state kinetics to
evaluate role of these dual sites in the mechanism of binding.4 Results from the kinetic measurements demonstrate
two-step binding of PAI-1 to vitronectin. Significantly, this
kinetic work demonstrates that the two-phase binding
mechanism mediates the formation of stoichiometric 1:1
complexes of vitronectin and PAI-1; it is not limited to
assembly of higher order complexes.
The verification of a second PAI-1-binding site on
vitronectin apart from the N-terminal somatomedin B
domain is important in constructing a unified picture of the
interplay between PAI-1 and vitronectin that can account for
their multiple roles in the circulation and the extracellular
matrix. Both PAI-1 and vitronectin have different activities
depending upon their localization. The anti-protease activity of PAI-1 in the circulation is targeted specifically at pericellular proteolysis when localized to the extracellular
matrix or cell/matrix boundary. A paradox has emerged
from studies in animal models that have shown dose-dependent effects of PAI-1 in regulating tumor-growth and
angiogenesis (18, 75), with low and high concentrations giving opposite effects. There is currently no mechanism to
explain why low concentrations of PAI-1 have anti-adhesive
and anti-tumor effects, whereas high levels of PAI-1 are proadhesive and pro-tumorigenic. The availability of two binding sites for PAI-1 on vitronectin may help rectify this para-

3

C. R. Schar, J. K. Jensen, A. Christenson, G. E. Blouse, P. A. Andreason, and C. B.
Peterson, submitted for publication.
4
G. E. Blouse, D. M. Dupont, C. R. Schar, J. K. Jensen, K. H. Monor, J. Y. Anagli, H.
Gardsvoll, M. Ploug, C. B. Peterson, and P. A. Andreasen, submitted for
publication.
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dox. Thus, the dose-dependent PAI-1 effects may arise from
the assembly of oligomeric vitronectin-PAI-1 that occurs
when both binding sites are occupied. Clearly, further work
is needed to test this hypothesis.
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